English | Français
English | Français
iC BIOSOLUTIONS is a biotech company addressing chronic inflammatory and degenerative diseases.
By developing first-in-class acellular secretome therapeutics, we harness the regenerative and anti-inflammatory potential of stem cells to deliver a safer, more consistent, and scalable therapeutic model.
We are pioneering a new class of biologics based on the regenerative signaling naturally released by stem cells.
By eliminating the inherent challenges of live-cell administration, acellular secretome therapy offers a safer, more consistent, and more scalable alternative, while preserving strong regenerative and anti-inflammatory properties.
Validated through rigorous in vitro and ex vivo assays, our approach demonstrates biological activity and a tolerability profile supporting its readiness for clinical translation.
Regenerative biological activity
Modulates core inflammatory and regenerative pathways through controlled paracrine signaling.
Safety by design
Acellular, donor-independent format designed to reduce biological variability and mitigate risks associated with viable cell administration.
Clinically translatable
Developed within a controlled manufacturing framework supporting reproducibility, scalability, and regulatory alignment.
The iC BIOSOLUTIONS platform is built on stable and renewable, GMP-compliant stem cell banks, providing a controlled and reproducible biological source for secretome production. Combined with directed differentiation, acellular manufacturing, and rigorous quality control, this end-to-end process enables the development of robust, clinically usable regenerative biologics.
iC BIOSOLUTIONS is developing a secretome-based therapeutic platform, initially validated in veterinary medicine and designed for stepwise expansion to companion animals, with long-term translation to human health.
Built around a focused pipeline, the platform advances ICB001 as the first clinical generation of secretome therapeutics, targeting chronic joint diseases in horses.
Beyond this initial product, ongoing R&D leverages the platform as a discovery and optimization engine, enabling next-generation secretome therapeutics with enhanced biological activity and expanded therapeutic breadth.
Leveraging its robust scientific foundation, the iC BIOSOLUTIONS platform extends beyond veterinary use to enable innovative programs in human health. Its fully integrated, end‑to‑end development model, combined with strategic collaborations, supports the translation of core technologies into dedicated human health applications.
Equine health
Lead clinical application
Our lead product candidate, ICB001, is being developed to address chronic joint diseases in horses, providing initial clinical validation of the iC BIOSOLUTIONS platform.
Companion animals
Next-step veterinary applications
Building on clinical experience in horses, iC BIOSOLUTIONS is rapidly extending its secretome approach to dogs and cats.
These applications go beyond joint diseases and target selected severe chronic inflammatory conditions where current therapeutic options remain limited.